5fqb: Difference between revisions
No edit summary |
No edit summary |
||
Line 20: | Line 20: | ||
</div> | </div> | ||
<div class="pdbe-citations 5fqb" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5fqb" style="background-color:#fffaf0;"></div> | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 15:40, 6 November 2017
Crystal Structure of Bacillus cereus Metallo-Beta-Lactamase with 2CCrystal Structure of Bacillus cereus Metallo-Beta-Lactamase with 2C
Structural highlights
Function[BLA2_BACCE] Can hydrolyze carbapenem compounds. Publication Abstract from PubMedbeta-Lactamases enable resistance to almost all beta-lactam antibiotics. Pioneering work revealed that acyclic boronic acids can act as 'transition state analogue' inhibitors of nucleophilic serine enzymes, including serine-beta-lactamases. Here we report biochemical and biophysical analyses revealing that cyclic boronates potently inhibit both nucleophilic serine and zinc-dependent beta-lactamases by a mechanism involving mimicking of the common tetrahedral intermediate. Cyclic boronates also potently inhibit the non-essential penicillin-binding protein PBP 5 by the same mechanism of action. The results open the way for development of dual action inhibitors effective against both serine- and metallo-beta-lactamases, and which could also have antimicrobial activity through inhibition of PBPs. Structural basis of metallo-beta-lactamase, serine-beta-lactamase and penicillin-binding protein inhibition by cyclic boronates.,Brem J, Cain R, Cahill S, McDonough MA, Clifton IJ, Jimenez-Castellanos JC, Avison MB, Spencer J, Fishwick CW, Schofield CJ Nat Commun. 2016 Aug 8;7:12406. doi: 10.1038/ncomms12406. PMID:27499424[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
|